Podcasts about Duke University

Send us a textThis episode dives into the life of Joan Trumpauer Mulholland, a significant figure in the Civil Rights Movement. The discussion covers her early life and influences, including the stark contrasts between her parents' views on race and social justice. Her transition from Duke University to becoming a full-time activist is highlighted, emphasizing her involvement in significant events like the Freedom Rides, the Woolworths sit-in, and Freedom Summer 1964. We also touch on the dangers she faced, lessons learned, and her lasting impact. Furthermore, her later life, her commitment to raising her children, and her continuous efforts through the Joan Trumpauer Mulholland Foundation are explored, offering insights into actionable ways to support social justice causes.The Joan Trumpauer Mulholland FoundationWays to support Minneapolis:Stand With Minnesota MPLS Mutual AidMN NOICEImmigrant Law Center of MinnesotaCommunity Aid Network MNInternational Institute of MinnesotaParents for Good - Anoka-HennepinInterfaith Coalition on ImmigrationMonarcaMetta Coffee

Evolution with natural selection involves an intricate mix of the random and the driven. Mutations are essentially random, while selection pressures work to prefer certain outcomes over others. There is tremendous divergence of species over time, but also repeated convergence to forms and mechanisms that are unmistakably useful. We see this clearly in eyes and fins, but the basic pattern also holds for brains and forms of social organization. I talk with philosopher Rachell Powell about what these ideas mean for humans, other terrestrial species, and also for forms of life we have not yet encountered.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2026/01/26/342-rachell-powell-on-evolutionary-convergence-morality-and-mind/Support Mindscape on Patreon.Rachell Powell received her Ph.D. in philosophy from Duke University. She is currently a Professor of Philosophy at Boston University. She has held fellowships at the National Humanities Center, the American Council of Learned Societies, the Konrad Lorenz Institute for Evolution and Cognition Research, the National Evolutionary Synthesis Center, the Berlin School of Mind and Brain at Humboldt University, and the Center for Genetic Engineering and Society at North Carolina State University.Boston University web pagePhilPapers publicationsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Feeling that our life is meaningful - that we add value to the world and are valued by the people around us, isn't just a good feeling, it's a fundamentally necessary one. In fact, the need to matter is a universal human motive, second only to the needs of food and shelter.  On this episode we'll talk to author Jennifer Wallace about her new book on the topic of mattering, why we're in a “mattering deficit,” the worrying impact this is having on our physical and emotional health, and what we can do to change that. And Duke researcher Patty Van Cappellen will share studies showing how spirituality and religious community can instill a deep sense of meaning in life that contributes to true human flourishing. Jennifer Wallace is an award-winning journalist and the author of Mattering. You can find more about her work on her website.Patty Van Cappellen, Ph.D., is an associate research professor at the Social Science Research Institute and the Department for Psychology and Neuroscience at Duke University.

In this week's Short Suck, we revisit the 2006 Duke Lacrosse scandal—the case that felt like an open-and-shut story of privilege and violence… until the facts started falling apart, the DNA didn't match, and the real rot turned out to be the rush to convict. It's a brutal look at how media narratives, campus outrage, and a DA chasing votes can turn “everyone knows what happened” into one of the most infamous examples of what happens when due process gets trampled.For Merch and everything else Bad Magic related, head to: https://www.badmagicproductions.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

With the national championship in the rearview mirror, we turn our focus to 2026 with our first official podcast of the preseason. In this episode, we unveil our way-too-early top 12s and take a closer look and which teams have the most continuity and best schedules, and which crushed the transfer portal. Who's too high, who's too low? Let us know! Plus, a quick roundup of the latest news, from portal signings to early NFL Draft declarations and the brewing legal fight between Duke University and Darian Mensah.Timecodes: 0:00 - Intro4:44 - News Update21:17 - Way-Too-Early Top 12sSupport the show!: https://www.patreon.com/solidverbalSee omnystudio.com/listener for privacy information.

Transfer madness continues, as Duke University has sued to effectively prevent QB Darian Mensah from switching schools. Meanwhile, the college basketball world is up in arms over Charles Bediako's return to Alabama three years after he signed a contract with the San Antonio Spurs. Sportico legal analyst Mike McCann returns to break it all down. Learn more about your ad choices. Visit megaphone.fm/adchoices

If your brand feels too small to matter, this blueprint shows why that might be your unfair advantage.In this episode of Sharkpreneur, Seth Greene interviews Mark Rampolla, Co-Founder and Co-Managing Partner at GroundForce Capital, who unpacks how a niche idea became a global category. Mark shares the strategy that took ZICO from yoga studios in NYC to nationwide shelves, the discipline behind constant pitching and fundraising, and why exits aren't the finish line. He also discusses his new book on putting freedom first, and his work at Ground Force Capital (backer of brands like Liquid Death and Beyond Meat), helping founders scale both their companies and their lives.Key Takeaways:→ Why “inch-wide, mile-deep” focus beats broad launches for breakthrough CPG growth.→ How pairing a product with a specific usage occasion (post-hot yoga) created early traction.→ The surprising first hurdle: taste—and how “preach to the choir” accelerates momentum.→ Fundraising reality: why you either get profitable fast or get great at raising—continuously.→ The nine-year “overnight success” mindset and the decade-long horizon most wins require.Mark Rampolla is Co-Founder and Co-Managing Partner at GroundForce Capital (GFC), where he works closely with founders and teams to build impactful businesses. He has represented GFC on the boards of leading companies, including Vive Organic, OWYN, Liquid Death, Kinder Farms, Flying Embers, and ZICO Rising. Prior to GFC, Mark founded and served as CEO of ZICO Beverages, pioneering the coconut water category and growing the brand into a global leader before its acquisition by The Coca-Cola Company in 2013. Earlier in his career, he held senior management roles at International Paper, overseeing joint ventures across Latin America and the Caribbean. A Peace Corps alum, Mark has advised more than 100 CEOs, raised over $1B, and invested in 40+ social-impact startups. He is the author of High-Hanging Fruit and holds degrees from Marquette University and Duke University.Connect With Mark:Website: https://www.markrampolla.co/Instagram: https://www.instagram.com/markrampolla/LinkedIn: https://www.linkedin.com/in/marksrampolla/

Maria Morera Johnson interviews Meigs Turgeon, Special Assistant to the President at Holy Cross Family Ministries, about the important priest and brothers of the Congregation of Holy Cross. Meigs Turgeon, Special Assistant to the President, Fr. Fred Jenga, C.S.C., at Holy Cross Family Ministries. Meigs joined HCFM from Austin, Texas where he most recently served as Assistant Director of the Holy Cross Institute at St. Edward's University and Adjunct Professor of Christian Theology. He graduated with a Master of Divinity from Duke University; is an expert in Holy Cross Charism and Spirituality, a prolific writer and speaker on different faith-based topics.   Link in Show: Holy Cross Family Ministries

  On this week's episode of Tying it Together, Dr. Bruce Jentleson joins host Tim Boyum to explain the story behind all the foreign policy battles garnering the attention of President Trump — from Iran, Venezuela, Ukraine, to Greenland.  Jentleson is a professor at the Sanford School of Public Policy at Duke University.  He's a former senior adviser at the State Department under the Obama and Clinton administrations. He also served as a senior foreign policy advisor to the Al Gore presidential campaign and lectures around the world on foreign policy.

Jason and Mike weigh-in on all the drama in Buffalo coming off the Bills loss to the Broncos. Duke University is really suing QB Darian Mensah to keep him at Duke. And Jason tells you if Jalen Brunson calling a Knicks "players only" meeting will get them back on track!See omnystudio.com/listener for privacy information.

In this episode, we explore the Society for Vascular Surgery (SVS) Quality Improvement (QI) Consulting Program, a free member benefit that supports vascular surgeons in designing, executing, and refining QI projects across all stages—from problem identification to dissemination. We're joined by Dr. Samantha Minc, a vascular surgeon and faculty member at Duke University, and Dr. Ashley Vavra, an Associate Professor of Surgery at Northwestern Feinberg School of Medicine and chair of the SVS Quality Improvement Committee. Both bring extensive experience in vascular care and quality-focused clinical practice. Together, they break down how the QI Consulting Program helps clinicians: Develop SMART goals and clear project aims Identify stakeholders and select appropriate methodologies Organize timelines and communication plans Track process measures and assess intervention impact Troubleshoot challenges and prepare presentation or publication materials They also outline what the program does not provide—such as data analysis, formal instruction, or long-term mentorship—to help members understand its intended scope. The application process is straightforward: SVS members may apply during the first two weeks of each month, with up to five projects accepted per cycle. This episode stresses the value of QI in vascular surgery and offers a practical, accessible overview of how the QI Consulting Program can support meaningful improvement efforts in vascular practices. Learn more: https://vascular.org/vascular-specialists/practice-and-quality/quality/quality-improvement-consulting-program   *Gore is a financial sponsor of this podcast, which has been independently developed by the presenters and does not constitute medical advice from Gore. Always consult the Instructions for Use (IFU) prior to using any medical device.

In the aftermath of the U.S. intervention in Venezuela, we explore how rising political divides are leading to bigger swings in America's foreign policy — and what that means for our future in the liberal international order.In her book Polarization and International Politics: How Extreme Partisanship Threatens Global Security, Rachel Myrick argues that polarization reshapes the nature of constraints on democratic leaders, which in turn erodes the advantages democracies have in foreign affairs. We discuss how the pendulum swing from one administration to another leads to instability in foreign affairs. As a result, Myrick says the United States loses both reliability as an ally and credibility as an adversary. Myrick also questions the longstanding thinking that having a common enemy to focus on is enough to overcome polarization, as it was during the Cold War.Myrick is the Douglas & Ellen Lowey Associate Professor of Political Science at Duke University. Her research explores how partisan polarization affects foreign policymaking in democracies, with an emphasis on U.S. national security policy.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this Salcedo Storm Podcast:Mike Howell is the President of the Oversight Project. He has senior experience from different oversight positions in the Executive Branch, on Capitol Hill, and in representing private parties in oversight and investigation matters. He is a graduate of Duke University and Emory Law School.

In this episode of Health Matters, host Courtney Allison is joined by Dr. Rekha Kumar, endocrinologist and primary care physician at NewYork-Presbyterian and Weill Cornell Medicine, to unpack the science behind aging well. They discuss biohacking, longevity, and health span, separating evidence-based strategies from social media hype and exploring what truly helps us age well.What You'll Learn in This EpisodeWhat “biohacking” really means● How biohacking ranges from simple lifestyle optimization to high-tech, experimental interventions● The difference between lifespan (how long you live) and health span (how long you live well)The Longevity Pyramid● Why the foundation of healthy aging is built on:SleepMovement and strength trainingNutritionStress managementSocial connection● How advanced tools and supplements sit at the top—and why they should never replace the basicsWearables and Tracking● How devices like smartwatches, glucose monitors, and fitness trackers can support behavior change● When tracking becomes counterproductive or stressfulPeptides and “Anti-Aging” Supplements● What's proven (e.g., metformin, GLP-1 receptor agonists)● What's still experimental or under-studied (BPC-157, sermorelin, NAD boosters)Nootropics and Cognitive Enhancers● Everyday nootropics like caffeine● The role of L-theanine for “calm focus”● Myths around perfectly timed caffeine and cortisol rhythmsNutrigenomics and Personalized Nutrition● How genes can influence responses to foods (e.g., lactose intolerance, APOE and saturated fat)● Why many direct-to-consumer genetic tests may overpromiseThe Gut Microbiome● The role of Akkermansia muciniphila in metabolic health● How medications like metformin and GLP-1s may positively shift gut bacteria● What's still unknown about probiotic supplementationGenetic and Biomarker Testing● The difference between actionable medical insights and “information overload”● Why results of unknown significance can cause unnecessary anxietyThe Big Takeaways● There are no true shortcuts to longevity● Sustainable habits beat quick fixes● Our biology is built for rhythms, not constant optimizationFeatured ExpertAbout Rekha B. Kumar, M.D., M.S.Dr. Rekha B. Kumar is an attending endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center and an associate professor of Clinical Medicine at Weill Cornell Medicine. She specializes in adult primary care and endocrinology and has academic expertise in the diagnosis and treatment of various endocrine disorders, including obesity/weight management, type 2 diabetes, polycystic ovarian syndrome (PCOS), thyroid disorders, as well as metabolic bone disease.Dr. Kumar completed her undergraduate studies at Duke University and received her masters degree in Physiology from Georgetown University. She received her M.D. from New York Medical College and completed her residency training in Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the NewYork-Presbyterian/Weill Cornell Medical Center and the Memorial Sloan Kettering Cancer Center. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine.Coming Up NextIn the next episode of Health Matters, we'll explore brain health and the short- and long-term effects of alcohol on the brain with Dr. Hugh Cahill. Subscribe and follow Health Matters on Apple Podcasts, Spotify, or wherever you listen to stay up to date with expert-driven conversations on living well at every stage of life.About Health MattersHealth Matters is your bi-weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

What an honor to begin 2026 with an inspiring conversation with Sports Medicine legend, and AAOS President Dr. Annunziato "Ned" Amendola!We cover a lot of ground in this conversation, his legacy work at Duke, AAOS, NBA shoe consultancy, mentorship, cartilage replacement, even Italian food!!What a towering figure in sports medicine and foot and ankle care at Duke University, where he serves as a distinguished professor, chief of sports medicine, and executive director of the James R. Urbaniak, MD, Sports Sciences Institute. Since joining Duke in 2015 he has served as head team physician and chief medical officer for Duke Athletics, providing exceptional care to elite athletes while advancing innovative treatments for knee and ankle injuries. Internationally renowned for pioneering arthroscopic and biologic resurfacing techniques that have transformed cartilage repair and rehabilitation, Dr. Amendola has authored over 300 peer-reviewed articles, secured numerous research grants, and earned prestigious honors such as the Excellence in Research Award, Cabaud Memorial Award, O'Donoghue Award, and the Kappa Delta Ann Doner Vaughn Award. His leadership culminated in serving as President of the American Academy of Orthopaedic Surgeons (AAOS), where he has championed excellence in musculoskeletal care and mentored countless surgeons worldwide.Beginning his journey in Canada with training at the University of Western Ontario and fellowships in sports medicine and foot and ankle surgery, he previously held key roles including director of sports medicine at the University of Iowa. His contributions have earned him additional accolades like the Achilles Award from ISAKOS, the Roger Mann and Leonard Goldner Awards from the American Orthopaedic Foot and Ankle Society, and induction into the AOSSM Hall of Fame. Join us (and Skeletoni) at the next AAOS meeting: https://www.aaos.org/Clinic: https://www.dukehealth.org/find-doctors-physicians/annunziato-ned-amendola-mdPlease support our Sponsor, Anika Therapeutics: https://anika.com/Duke World Games: https://ryortho.com/2026/01/duke-health-is-warming-up-early-and-ortho-is-leading-the-charge/Support the show

Dave Chatterjee, Adjunct Associate Professor at Duke University,  explains how scale, speed, and surprise are reshaping cyber threats and why many organizations remain dangerously reactive. He shares his Commitment-Preparedness-Discipline (CPD) framework along with ways that leaders can move beyond checkbox compliance by treating cybersecurity as a strategic business priority. Key Takeaways:  The three underestimated AI risks that leaders often overlook, and how AI must be used to defend against AI-driven cyber threats Why deepfake attacks represent a systemic risk at both the individual and organizational levels Practical steps individuals can take to reduce exposure to fraud, impersonation, and data loss How better cybersecurity hygiene creates trust, resilience, and competitive advantage Guest Bio: Dave Chatterjee, Ph.D., is a leading authority on cybersecurity strategy, governance, and AI security. As the creator of the Commitment-Preparedness-Discipline (CPD) framework, he helps organizations worldwide build resilient, high-performance security cultures. His recent work explores the convergence of artificial intelligence, cybersecurity, and business resilience, addressing challenges such as AI exploitation, deepfake manipulation, and the secure integration of intelligent systems. Dr. Chatterjee is the author of "Cybersecurity Readiness: A Holistic and High-Performance Approach" and the cybercrime-themed novel "The DeepFake Conspiracy", which illustrates the emerging risks and ethical dilemmas at the intersection of AI and cyber defense. His thought leadership has appeared in The Wall Street Journal, Forbes, USA Today, Business Insider, California Management Review, Business Horizons, MIS Quarterly, and Journal of Management Information Systems. As host of the acclaimed Cybersecurity Readiness Podcast Series, he has engaged leading practitioners, policymakers, and researchers in discussions on topics such as agentic AI, post-quantum readiness, and AI-driven threat detection. A trusted advisor to Fortune 500 firms and government agencies, Dr. Chatterjee delivers high-impact keynotes and moderates CXO panels worldwide, advancing dialogue on how to turn AI risk into organizational resilience. ---------------------------------------------------------------------------------------- About this Show: The Brave Technologist is here to shed light on the opportunities and challenges of emerging tech. To make it digestible, less scary, and more approachable for all! Join us as we embark on a mission to demystify artificial intelligence, challenge the status quo, and empower everyday people to embrace the digital revolution. Whether you're a tech enthusiast, a curious mind, or an industry professional, this podcast invites you to join the conversation and explore the future of AI together. The Brave Technologist Podcast is hosted by Luke Mulks, VP Business Operations at Brave Software—makers of the privacy-respecting Brave browser and Search engine, and now powering AI everywhere with the Brave Search API. Music by: Ari Dvorin Produced by: Sam Laliberte  

Luke Hedrick, Dave Furfaro, and recurrent RFJC guest Robert Wharton are joined again today by Nicole Ng to discuss the FIBRONEER-IPF trial investigating Nerandomilast in patients with IPF. This trial was published in NEJM in 2025 and looked at Neradomilast vs placebo for treating patients with IPF, on or off background anti-fibrotic therapy. This agents is now FDA approved for pulmonary fibrosis, and understanding the trial results is essential for any pulmonary physician treating patients with IPF or progressive pulmonary fibrosis. Article and Reference Today’s episode discusses the FIBRONEER-IPF trial published in NEJM in 2025. Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS; FIBRONEER-IPF Trial Investigators. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12;392(22):2193-2202. doi: 10.1056/NEJMoa2414108. Epub 2025 May 18. PMID: 40387033. https://www.nejm.org/doi/abs/10.1056/NEJMoa2414108 Meet Our Guests Luke Hedrick is an Associate Editor at Pulm PEEPs and runs the Rapid Fire Journal Club Series. He is a senior PCCM fellow at Emory, and will be starting as a pulmonary attending at Duke University next year. Robert Wharton is a recurring guest on Pulm PEEPs as a part of our Rapid Fire Journal Club Series. He completed his internal medicine residency at Mt. Sinai in New York City, and is currently a pulmonary and critical care fellow at Johns Hopkins. Dr. Nicole Ng is an Assistant Profess of Medicine at Mount Sinai Hospital, and is the Associate Director of the Interstitial Lung Disease Program for the Mount Sinai National Jewish Health Respiratory Institute. Infographic Key Learning Points Why this trial mattered IPF therapies remain limited: nintedanib and pirfenidone slow (but do not stop) decline and often cause GI side effects. Nerandomilast is a newer agent (a preferential PDE4B inhibitor) with antifibrotic + immunomodulatory effects. Phase 2 data (NEJM 2022) looked very promising (suggesting near-“halt” of FVC decline), so this phase 3 trial was a big test of that signal. Trial design essentials Industry-sponsored, randomized, double-blind, placebo-controlled, large multinational study (332 sites, 36 countries). Population: IPF diagnosed via guideline-aligned criteria with central imaging review and multidisciplinary diagnostic confirmation. Intervention: nerandomilast 18 mg BID, 9 mg BID, or placebo; stratified by background antifibrotic use. Primary endpoint: change in FVC at 52 weeks, analyzed with a mixed model for repeated measures. Key secondary endpoint: time to first acute exacerbation, respiratory hospitalization, or death (composite). Who was enrolled Typical IPF trial demographics: ~80% male, mean age ~70, many former smokers. Many were already on background therapy (~45% nintedanib, ~30–33% pirfenidone). Notable exclusions included significant liver disease, advanced CKD, recent major cardiovascular events, and psychiatric risk (suicidality/severe depression), reflecting class concerns seen with other PDE4 inhibitors. Efficacy: what the primary endpoint showed Nerandomilast produced a statistically significant but modest reduction in annual FVC decline vs placebo (roughly 60–70 mL difference). Importantly, it did not halt FVC decline the way the phase 2 data suggested; patients still progressed. Important nuance: interaction with pirfenidone Patients on pirfenidone had ~50% lower nerandomilast trough levels. Clinically: 9 mg BID looked ineffective with pirfenidone, so 18 mg BID is needed if used together. In those not on background therapy or on nintedanib, 9 mg and 18 mg looked similar—suggesting the apparent “dose-response” might be partly driven by the pirfenidone drug interaction Secondary and patient-centered outcomes were neutral No demonstrated benefit in the composite outcome (exacerbation/resp hospitalization/death) or its components. Quality of life measures were neutral and declined in all groups, emphasizing that slowing FVC alone may not translate into felt improvement without a disease-reversing therapy. The discussants noted this may reflect limited power/duration for these outcomes and mentioned signals from other datasets/pooling that might suggest mortality benefit—but in this specific trial, the key secondary endpoint was not positive. Safety and tolerability Diarrhea was the main adverse event: Higher overall with the 18 mg dose, and highest when combined with nintedanib (up to ~62%). Mostly mild/manageable; discontinuation due to diarrhea was relatively uncommon (but higher in those on nintedanib). Reassuringly, there was no signal for increased depression/suicidality/vasculitis despite psychiatric exclusions and theoretical class risk. How to interpret “modest FVC benefit” clinically The group framed nerandomilast as another tool that adds incremental slowing of progression. They emphasized that comparing absolute FVC differences across trials (ASCEND/INPULSIS vs this trial) is tricky because populations and “natural history” in placebo arms have changed over time (earlier diagnosis, improved supportive care, etc.). They highlighted channeling bias: patients already on antifibrotics may be sicker (longer disease duration, lower PFTs, more oxygen), complicating subgroup comparisons. Practical takeaways for real-world use All three antifibrotics are “fair game”; choice should be shared decision-making based on goals, tolerability, dosing preferences, and logistics. Reasons they favored nerandomilast in practice: No routine lab monitoring (major convenience advantage vs traditional antifibrotics). Generally better GI tolerability than nintedanib. BID dosing (vs pirfenidone TID). Approach to combination therapy: They generally favor add-on rather than immediate combination to reduce confusion about side effects—while acknowledging it may slow reaching “maximal therapy.” Dosing guidance emphasized: Start 18 mg BID for IPF, especially if combined with pirfenidone (since dose reduction may make it ineffective). 9 mg BID may be considered if dose reduction is needed and the patient is not on pirfenidone (e.g., monotherapy or with nintedanib).

ADHD is not just about attention. It is about self-control, self-esteem, and what happens when the brain goes offline. Living with untreated ADHD is not just about missing assignments. It is about moving through the world without a reliable connection between what you know and what you do. In this conversation, I talk with Dr. Karin Varblow, a behavioral pediatrician, former teacher and social worker, neurodivergent adult, and mom to neurodivergent kids. We look closely at what untreated ADHD really costs over a lifetime, from self-esteem and identity to health, safety, relationships, and even life expectancy. Dr. Karin explains why ADHD is not simply a "school problem" and why kids who "know better" still cannot always do better in the moment. She shares her "know and go" model of the brain, which helps make sense of why lectures and bigger consequences do not lead to different behavior, and why kids so often feel confused and ashamed by their own actions. We also talk about sleep, airway, co-occurring conditions, and how things like anxiety, trauma, allergies, and disordered sleep can overlap with ADHD or even mask it. Dr. Karin breaks down what good treatment actually looks like in real life, including medication, parent training, behavior supports, and making daily life more stimulating and relevant for the ADHD brain. If you have ever wondered whether ADHD "really" needs treatment, or felt discouraged by mixed messages, this episode will help you see the bigger picture with more clarity and more compassion for you and your child. Key Takeaways Untreated ADHD is not just about school performance. It affects self-esteem, identity, health, safety, relationships, income, and even life expectancy over time. Research shows that people with untreated ADHD have higher rates of emergency room visits, poverty, incarceration, and an average life expectancy that is years shorter than their non-ADHD peers. Treatment meaningfully improves these outcomes. ADHD is both overdiagnosed and underdiagnosed, and it often shows up alongside other conditions like anxiety, depression, learning differences, sleep disorders, allergies, GI issues, and trauma. Sorting out "what's what" takes time and thoughtful evaluation. Effective ADHD treatment is not one thing. The strongest evidence supports a combination of medication and behavior modification, with behavior modification defined as training and support for parents, not "fixing the child" in a weekly session. Behavior plans that focus only on lectures and bigger consequences usually miss the mark. Most kids already know the rules. The problem is not a lack of knowledge, it is a lack of access to that knowledge in the moment. Dr. Karin's "know and go" model helps explain this: the "know" part of the brain holds rules, values, and experience; the "go" part drives behavior. In ADHD, especially around non-preferred tasks, the "go" can take off before the "know" ever gets a say. That disconnect is why kids so often say "I don't know why I did that" and mean it. They are not being manipulative. They are genuinely confused and often ashamed, because their behavior does not match what they actually believe or want. ADHD brains do have strong executive function in areas of high interest. A child who cannot organize themselves around homework may show incredible focus, planning, and follow-through when building Legos or diving into a favorite topic. Sleep, breathing, immune function, and overall health matter. Airway issues, disordered sleep, allergies, and inflammation can all worsen attention, regulation, and behavior, and sometimes even mimic ADHD. Addressing these pieces is part of good care. Supporting a child with ADHD means changing the story from "try harder" to "let's change how we're asking, what we're asking, and how we're supporting you." When adults focus on relevance, relationship, and realistic support, kids get more access to their best selves. About Karin Varblow Dr. Karin Varblow is a behavioral pediatrician and neurodivergence specialist who has built a career around coordinated, whole-family ADHD care. She earned her BA from Duke University and her MD from The George Washington University School of Medicine as a National Health Service Corps Scholar, and completed her Pediatrics residency at INOVA Fairfax Hospital for Children. Dr. Varblow's work is shaped by her unique path as a former educator and social worker, a former general pediatrician, a parent in a neurodiverse family, and an individual with ADHD herself. She supports families through medication management, parent support, behavior modification, care coordination, advocacy, and strategy development, with a focus on helping children thrive in real life, not just "meet expectations." About Your Host, Gabriele Nicolet I'm Gabriele Nicolet, toddler whisperer, speech therapist, parenting life coach, and host of Complicated Kids. Each week, I share practical, relationship-based strategies for raising kids with big feelings, big needs, and beautifully different brains. My goal is to help families move from surviving to thriving by building connection, confidence, and clarity at home. Complicated Kids Resources and Links:

In 2025, Ballard High School's Cassidy Armstrong turned a season nearly lost to injury into one of the strongest postseason runs in the country.The Seattle senior, committed to Duke University, entered the fall coming off a hip stress fracture that erased her entire junior track season. Six weeks unable to walk. No running until August. No early-season races to test fitness or confidence.Armstrong didn't race until October 31st. She opened with a second-place finish at the SeaKing District Championships. Days later, she repeated the result at the WIAA 3A State Meet, finishing just behind Mercer Island's Sophia Rodriguez. Then the season stretched. At NXR Northwest in Spokane, Armstrong placed fifth on the new course, earning her first-ever qualification to Nike Cross Nationals.In December, on the sport's biggest stage, she delivered again. Armstrong finished 18th at Nike Cross Nationals, securing All-American honors and closing the year ranked 24th nationally by DyeStat — the second-highest of any high school girl on the West Coast.This season asked for patience. Cassidy trained without proof, raced without momentum, and trusted that the work would show up eventually. When it did, it showed up at the biggest moments.As she looks ahead to Duke and the next chapter of her career, this season stands as proof that timing, belief, and resilience can be just as powerful as raw fitness.Tap into the Cassidy Armstrong Special.Consider leaving a follow and a five-star review. Instagram: ⁠https://www.instagram.com/thesundayshakeout/

This episode, recorded live at the Becker's 13th Annual CEO + CFO Roundtable, features Trudy Sullivan Stoudamire, MBA Senior Vice President, Chief Marketing & Communications Officer, Duke University Health System, as she outlines Duke Health's growth strategy centered on expanding access across North Carolina. She discusses aligning marketing and communications with system growth, building partnerships, strengthening brand trust, and leading with purpose and hope during industry change.

Broadcast from KSQD, Santa Cruz on 1-01-2025: An emailer asks about omega-3 supplementation for memory at age 72. Dr. Dawn advises checking that fish oil capsules contain adequate DHA—at least 1,000 mg—since many omega-3 products have low DHA levels. She notes Medicare covers the same testing at standard labs as proprietary labs like OmegaQuant that charge patients directly. Beyond omega-3s, she emphasizes glucose control (hemoglobin A1c below 5.6) since the enzyme that breaks down insulin also clears beta-amyloid, and weight training to raise brain-derived neurotrophic factor (BDNF), which promotes new synapse formation essential for memory. Dr. Dawn reviews Popular Science's top 2025 health innovation: eye drops from Lens Therapeutics containing aceclidine that correct age-related farsightedness for 10 hours. The drops shrink the pupil to increase depth of field, improving near vision by three or more lines on eye charts within 30 minutes without affecting distance vision. Side effects include eye irritation, dimmed night vision, and headache. She describes Duke University's breakthrough allowing heart transplants from circulatory death donors using an on-table reanimation technique. This could expand the pediatric donor pool by 20%—critical since up to 20% of children die waiting for transplants. Dr. Dawn celebrates CAR-T immunotherapy for multiple myeloma, which saved her husband's life. Of 97 heavily pretreated patients, 38% achieved complete remission still present at five years, with over 50% total survival. The therapy removes T-cells, uses CRISPR to add receptors targeting cancer cell antigens, then reinfuses the modified cells. She highlights a UC Davis study showing remote blood pressure monitoring with home technology, education, and coaching dropped patients' average blood pressure from 150/80 to 125/74 in months—low-tech with high impact. Dr. Dawn explains the Nano Knife for prostate cancer, which uses localized electrical pulses delivered through thin wires to destroy tumors while sparing surrounding nerves. This minimally invasive approach could reduce erectile dysfunction and incontinence common with traditional surgery. She describes Gilead's Sunlenca, a twice-yearly injection for HIV prevention that's 99% effective. At $14,000 per injection in the US, proceeds help fund access in resource-limited countries where it can be distributed like a vaccination. Dr. Dawn discusses Journavx (suzetrigine), a new non-opioid pain medication working on sodium channels to block pain signals before reaching the brain. At $30 for 50 pills on GoodRx, it offers an alternative for surgical pain in patients with addiction history or genetic vulnerability to opioid dependence. She details the landmark case of Baby KJ, the first person to receive personalized CRISPR gene therapy. Born with a CPS1 enzyme deficiency causing toxic ammonia buildup, KJ was too small for liver transplant. Scientists identified his specific mutation and used CRISPR base editing delivered via lipid nanoparticles to correct a single DNA letter—changing an A to G—in his liver cells which restored enough function to be discharged home. Dr. Dawn reports surprising findings that COVID mRNA vaccines amplify cancer immunotherapy. Lung cancer patients who received COVID vaccination within 100 days of checkpoint inhibitor treatment had 56% three-year survival versus 31% for unvaccinated patients. The mechanism is unknown but may involve mRNA generally alerting the immune system. She revisits research showing Zostavax shingles vaccination reduced dementia risk by 20% over seven years. A natural experiment in Wales—where an age cutoff created comparable vaccinated and unvaccinated groups—provided strong evidence that preventing herpes zoster inflammation protects brain health. Dr. Dawn concludes with Huntington's disease breakthrough: microRNA therapy delivered by virus directly into the brain slowed disease progression by 75% over three years. The microRNA binds to Huntington protein mRNA, preventing ribosome translation and toxic protein production. Some patients returned to work; others expected to need wheelchairs are still walking.

In this powerful episode, Laura is joined by Dr. Keisha Bentley-Edwards, Associate Professor at Duke University's School of Medicine and Co-Director of Duke CTSI Center for Research, Community Engagement, Social Impact and Trust (CREST Center), for a timely conversation on rethinking resilience. Inspired by Dr. Bentley-Edwards' article "I Am Not (Your) Superwoman, Black Girl Magic, or Beautiful Struggle: Rethinking the Resilience of Black Women and Girls," this episode explores the cultural narratives that celebrate Black women's strength while often ignoring the profound physical, emotional, and psychological costs of relentless resilience. Together, Laura and Keisha unpack the tensions between pride in endurance, cultural expectations like the "Strong Black Woman," and the growing body of research showing how these narratives contribute to health inequities across the lifespan. Dr. Bentley-Edwards offers insight into how expectations of resilience often begin in childhood for Black girls, shaping adult experiences of stress, coping, and wellbeing. The conversation moves beyond critique toward possibility—imagining models of resilience that center sustainable wellness, community care, and structural accountability, rather than individual endurance alone. Dr. Bentley-Edwards also reflects on what Black women can do in service of themselves and Black girls, and what we must collectively demand from systems, institutions, and leaders. Anchored in Season 8's theme, "Leaning Into Joy," this episode invites listeners to consider how joy, rest, alignment, and community are not indulgences, but essential counterweights to harmful expectations of strength.   About Dr. Keisha Dr. Keisha Bentley-Edwards is an Associate Professor at Duke University's School of Medicine and Co-Director of Duke CTSI Center for Research, Community Engagement, Social Impact and Trust (CREST Center). She is also the Associate Director of Research for the Samuel DuBois Cook Center on Social Equity. Dr. Bentley-Edwards' research focuses on how racism, gender, and culture influence development throughout the lifespan, especially for African Americans. She is the Chair of the Society for Research in Child Development's Black Caucus. Her research emphasizes cultural strengths, including religiosity, and eliminating structural barriers to support healthy development in communities, families, and students, and in birth outcomes. Her research has been supported by the Robert Wood Johnson Foundation, IBM, and the National Institutes of Health. Dr. Bentley-Edwards shares her expertise on the causes and consequences of structural racism and bias on health, education and social outcomes with families, schools, policymakers, practitioners, and the media.   Connect with Dr. Keisha Website: https://www.drbentleyedwards.com/ LinkedIn: www.linkedin.com/in/kbentleyedwards    BWL Resources: Now enrolling for both the January  sessions of the Early Career and Mid-Career programs.  Learn more at https://blackwomanleading.com/programs-overview/ Full podcast episodes are now on Youtube.  Subscribe to the BWL channel today! Check out the BWL theme song here Check out the BWL line dance tutorial here Download the Black Woman Leading Career Journey Map - https://blackwomanleading.com/journey-map/   Credits: Learn about all Black Woman Leading® programs, resources, and events at www.blackwomanleading.com Learn more about our consulting work with organizations at https://knightsconsultinggroup.com/ Email Laura: info@knightsconsultinggroup.com Connect with Laura on LinkedIn Follow BWL on LinkedIn Instagram: @blackwomanleading Facebook: @blackwomanleading Youtube: @blackwomanleading  Podcast Music & Production: Marshall Knights  Graphics: Dara Adams Listen and follow the podcast on all major platforms: Apple Podcasts Spotify Stitcher iHeartRadio Audible Podbay  

“It is the heartbeat, the drumbeat. It's the heart line, it's the pipeline, it's just so many wonderful things that Black educators do.”Dr. Mazella Fullerhttps://antiracismandequity.com/antiracism-book-promo/“Black history is American history, and equity is not optional—it's essential.” Dr. Mazella Fuller shares her journey from K–12 classrooms to higher education, clinical social work, and national anti-racism leadership. She reflects on the power of Black educators to provide representation, cultural understanding, and pathways to student success—especially in spaces where Black voices are often marginalized.“We have to move from optics to outcomes.” Dr. Fuller is a licensed clinical social worker and educator who's spent nearly three decades transforming student support and developing outreach programs at Duke University's Counseling and Psychological Services. She co-authored the recently released "Antiblackness and the Stories of Authentic Allies: Lived Experiences in the Fight Against Institutionalized Racism" and also co-edited "Treating Black Women with Eating Disorders: A Clinician's Guide." Her advocacy centers on real allyship, mentorship as reparations, and integrating mental health with culturally responsive education.

Why do smart, capable people fall for scams even when the warning signs seem obvious in hindsight? In this episode, Dan Ariely joins us to examine how intuition often leads us in the wrong direction, especially under stress, uncertainty, or emotional pressure. A renowned behavioral economist, longtime professor of psychology and behavioral economics at Duke University, and bestselling author of Predictably Irrational, The Upside of Irrationality, Misbehaving, and Misbelief, Dan has spent decades studying why rational people consistently make choices that don't serve them.  We talk about the deeply human forces that shape how we decide who to trust, and how easily those instincts can be exploited in high-stakes situations involving fraud, financial loss, and digital deception. Dan shares a deeply personal story about surviving severe burns and the long process of self-acceptance that followed, using his own experience to show how hiding, blending in, and social pressure quietly influence behavior in ways most of us never stop to question.  We also explore why stress pushes people to search for patterns, stories, and a sense of control, even when those explanations aren't accurate. Dan explains how our minds operate like a "vintage Swiss Army knife," well suited for small, predictable communities but poorly equipped for modern risks like scams, cybersecurity threats, and low-probability, high-impact events. Topics include why near-misses teach the wrong lessons, why authority and urgency are so effective in manipulation, and why expecting people to be perfectly rational is a losing strategy. We also discuss practical ways to slow decisions down and bring in outside perspectives to help design safeguards that work with human nature. Show Notes: [01:52] Dan Ariely joins the episode to examine how human decision-making actually works under pressure. [03:41] How intuition can point us in the wrong direction during moments of stress and uncertainty. [05:26] Trust, authority, and urgency as core levers used in fraud and manipulation. [07:12] When decisions feel overwhelming, the brain's tendency to rely on shortcuts. [08:58] Dan explains why rational thinking often breaks down faster than we expect. [10:34] Near-misses and how they quietly reinforce false confidence instead of caution. [12:09] Why repeated exposure to risk doesn't necessarily make people better decision-makers. [13:55] Stress-driven pattern seeking and the human need for explanation and control. [15:32] Superstition, conspiracy thinking, and what they reveal about uncertainty tolerance. [17:18] Why modern threats like scams and cybercrime confuse brains built for simpler environments. [18:56] The "vintage Swiss Army knife" analogy and what it says about human cognition. [20:41] Authority cues and why skepticism often disappears in the presence of perceived expertise. [22:27] Slowing decisions down as one of the most reliable defenses against manipulation. [24:13] Dan reflects on how behavioral economics challenged traditional models of rational choice. [25:59] A personal story about surviving severe burns and the long path to self-acceptance. [27:44] How hiding and blending in can quietly shape behavior and self-perception. [29:31] Social pressure and its role in everyday compliance and risk-taking. [31:16] Why vulnerability doesn't look the way people expect it to. [33:02] Expecting perfect rationality and why that assumption consistently fails. [34:47] Designing systems that account for human limits instead of ignoring them. [36:33] The value of outside perspective when decisions carry real consequences. [38:19] Practical ways individuals can reduce risk by changing how they decide. [40:05] When slowing down matters more than having more information. [41:52] Applying behavioral insights to fraud prevention and digital safety. [43:38] Why better tools help, but mindset still plays a critical role. [45:24] Final thoughts on working with human nature rather than fighting it. [48:02] What listeners can take away about decision-making, risk, and self-awareness. Thanks for joining us on Easy Prey. Be sure to subscribe to our podcast on iTunes and leave a nice review.  Links and Resources: Podcast Web Page Facebook Page whatismyipaddress.com Easy Prey on Instagram Easy Prey on Twitter Easy Prey on LinkedIn Easy Prey on YouTube Easy Prey on Pinterest Dan Ariely Dan Ariely - LinkedIn Books by Dan Ariely Dan Ariely - YouTube

Looking where we have been reveals where we are headed. Those involved with sinister deeds should tremble. Those who have remained aligned with righteousness, rejoice. According to God 2026 is the year of the fix.Faith to Live By is recognized By Feedspot as among the top 15 Charismatic Christian Podcasts: https://podcast.feedspot.com/charismatic_christian_podcasts/ SHOW NOTES – Partial, view complete Show Notes Here.LINKS FROM SHOW CONTENT:Amanda Grace: https://www.youtube.com/shorts/jlkdxf1aUIE and https://www.youtube.com/watch?v=jiMQWEaOuM8Julie Green Prophecies: https://rumble.com/user/JulieGreenMinistriesLearn truth about Venezuela: https://x.com/TheRightMelissa/status/2007408531939717580 and https://www.theepochtimes.com/us/9-takeaways-from-trumps-address-on-operation-to-capture-maduro-5965704 “Miracles Today: The Supernatural Work of God in the Modern World.” By Craig Keener (PhD, Duke University) https://amzn.to/4jp1OjfSUPPORT: AFFILIATE SPONSORS: Home, Health and Home EntertainmentAffiliate Sponsors Main Page: https://pamelachristianministries.com/affiliate-sponsors-and-partnersQE Strong: Discover the benefits of quantum energy to overcome all sorts of ailments. Visit https://qestrong.com/ Use FTLB at check out for your discount. Hear my interview of founder, Rob Rene to learn more: https://open.spotify.com/episode/6qaVAO6aNAyXkCMzvmfkZ4Cue Streaming: Get Streaming content and your favorite TV networks for half of what cable costs without a contract. Sign up to subscribe today: https://faithtoliveby.mycuebroadcast.com Those interested in earning by securing subscribers yourself email me at: FaithToLiveBy@PamelaChristianMinistries.comDr. Zelenko: https://zstacklife.com/?ref=FTLB Use promo code FTLB for a 5% discount. Subscribers enjoy a 10% discount each and every month.

On today's show, I have two great guests joining me. The legend Michael Ian Black comes on at about one hour and 12 minutes but before that at 49 minutes, I speak with Venezuela expert and NYU historian Dr. Alejandro Velasco.   Subscribe and Watch Interviews LIVE : On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete   Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. This show is Ad free and fully supported by listeners like you!   Please subscribe now for as little as 5$ and gain access to a community of over 750 awesome, curious, kind, funny, brilliant, generous soul Michael Ian Black is a multi-media talent who's starred in numerous films and TV series, written and/or directed two films, is a prolific author and commentator, and regularly tours the country performing his ribald brand of jokes and observations.  Subscribe to his substack       Support him on Patreon He most recently starred in TVLand's "The Jim Gaffigan Show" and Comedy Central's "Another Period." He also reprised one of his iconic film roles in Netflix's "Wet Hot American Summer: Ten Years Later," and previously in "Wet Hot American Summer: First Day of Camp." His third standup comedy special, "Noted Expert," was released on Epix. Black's authored 11 books, including the recently released best seller, "A Child's First Book of Trump." He's written two well-received memoirs: "Navel Gazing: True Tales of Bodies, Mostly Mine (but also my mom's, which I know sounds weird)", and "You're Not Doing It Right: Tales of Marriage, Sex, Death and Other Humiliations." In 2012, he collaborated with conservative Meghan McCain on "America, You Sexy Bitch: A Love Letter to Freedom." He's the author of "My Custom Van (and 50 Other Mind-Blowing Essays That Will Blow Your Mind All Over Your Face)," and seven children's books, including "Cock-a-Doodle-Doo-Bop!," "Naked", "Chicken Cheeks," "The Purple Kangaroo," "A Pig Parade Is A Terrible Idea" and "I'm Bored." He also writes book reviews for the New York Times. Previously, Black released two stand-up specials, "Very Famous" and "I Am A Wonderful Man." He and Tom Cavanagh host the popular podcast, "Mike and Tom Eat Snacks." He also writes and hosts a podcast with Michael Showalter, "Topics," and his own interview podcast, "How To Be Amazing." He hosts "Debate Wars" on SeeSo, and he recently hosted "Easiest Game Show Ever" on Pop TV. Sketch comedy fans know Black's work on "The State," "Viva Variety," "Stella" and "Michael and Michael Have Issues" all of which he co-created, wrote and starred in. Other TV credits include quirky bowling alley manager 'Phil' on the NBC series "Ed," and his hilarious commentary on cable's "I Love the..." series. He recently starred in two hit web series that migrated to cable TV: "Burning Love" on E! and "You're Whole" on Adult Swim. Black's movie roles include "Slash," "Smosh: The Movie," "They Came Together," "Hell Baby," "This is 40," "Wet Hot American Summer," "Take Me Home Tonight," "Reno 911!: Miami," "The Ten" and "The Baxter." Black wrote and directed the film "Wedding Daze," starring Jason Biggs and Isla Fisher. He also co-wrote the comedy "Run, Fatboy, Run," directed by David Schwimmer and starring Simon Pegg, Hank Azaria and Thandie Newton.  ___________________________________________________________ Alejandro Velasco holds joint appointments in the Gallatin School and the Department of History, and was Executive Editor of the NACLA Report on the Americas from 2015 to 2021. Before NYU, he taught at Hampshire College, where he was Five College Fellow, and at Duke University. His research in the areas of social movements, urban politics, and democratization has won support from the Social Science Research Council, the Ford and Mellon Foundations, and the American Historical Association, among others, and has appeared in journals including the Hispanic American Historical Review, the Latin American Research Review, Labor, and others. Velasco's first book Barrio Rising: Urban Popular Politics and the Making of Modern Venezuela (University of California Press, 2015), won the 2016 Fernando Coronil Prize for best book on Venezuela, awarded biennially by the Section on Venezuelan Studies of the Latin American Studies Association. His teaching includes interdisciplinary courses on contemporary Latin America, among them seminars on human rights, cultural studies, and urban social movements; historical methods courses on 20th-century revolutions; graduate courses on urban political history and oral history; and workshops with primary and secondary school educators. A frequent media contributor, his editorials and analysis have appeared in NACLA, Nueva Sociedad, The Nation, the New York Times, the Washington Post, Current History, History News Network, BBC History Magazine, and others. Velasco also frequently contributes radio and television commentary in outlets including NPR, MSNBC, Al Jazeera, CBS, France 24, the BBC, and the CBC. On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Listen rate and review on Apple Podcasts Listen rate and review on Spotify Pete On Instagram Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on Twitter Pete Personal FB page Stand Up with Pete FB page Gift a Subscription https://www.patreon.com/PeteDominick/gift Send Pete $ Directly on Venmo

So many women grow up hearing that we should be able to have it all, yet very few of us are ever shown what that actually looks like in real life.In this episode, Emily welcomes Corinne Lowe, an associate professor of Business Economics and Public Policy. Corinne shares insights from her book, Having It All: What Data Tells Us About Women's Lives and Getting the Most Out of Yours, which examines gender wage gaps, structural discrimination, and the pressures women face when balancing career, family, and personal life.This conversation focuses on redefining success in a way that truly fits your values, being more intentional with your time, and finding fulfillment on your own terms. You'll also come away with practical strategies for workplace negotiations, rethinking productivity, and creating a more sustainable balance between work and life.Listen and Learn: How structural barriers limit women's career and wage growth, and encourage redefining success by focusing on personal fulfillment and leveling up within those realitiesHow women face systemic workplace barriers that collectively limit their opportunities and earnings, and why addressing these issues benefits everyoneDebunking myths about women's performance, showing that traits like negotiation skill and competitiveness are not inferior, and that focusing on evidence-based skill-building is what truly drives successUnderstanding and prioritizing your own “utility function” to help women focus on what matters to them, rather than constantly comparing themselves to othersHow to rethink your career as a tool for turning time into meaningful fulfillment, balance life's chapters intentionally, and confidently understand your market value to make work serve youReclaiming your time, setting boundaries, and making intentional choices to focus on what truly brings joy and meaning to your family and life, instead of being trapped by guilt, obligation, or unrealistic expectationsReframing parenting and self-care as “human capital” investment, showing how the time and care you give to your children and to yourself is meaningful, economically valuable, and essential for long-term wellbeingResources: Having It All: What Data Tells Us About Women's Lives and Getting the Most Out of Yours: https://bookshop.org/a/30734/9781250369512Corrine's Website: https://www.corinnelow.com Connect with Corrine on Social Media: https://www.instagram.com/corinnelowphd/https://www.linkedin.com/in/corinne-lowhttps://www.facebook.com/people/Corinne-Low Read More About Corrine's Work on Substack: https://corinnelow.substack.com/ About Corinne LowCorinne Low is an Associate Professor of Business Economics and Public Policy at the Wharton School of the University of Pennsylvania where she teaches an award-winning class (and was named one of Poets and Quants 40 MBA Professors under 40 in 2024). Her research on the economics of gender has been published in top journals such as the American Economic Review, Quarterly Journal of Economics, and Journal of Political Economy. Corinne and her work have been featured in major media outlets, such as The New York Times, CBS Mornings, Forbes, New York Magazine, and The Guardian. Corinne regularly speaks to and advises firms in addition to teaching in Wharton's Executive Education programs. She is the author of Having It All: What Data Tells Us About Women's Lives and Getting the Most Out of Yours. She received her Ph.D. in Economics from Columbia University, her B.S. in Economics and Public Policy from Duke University and formerly worked for McKinsey and Company.Related Episodes:398. Finding Joy in Your Relationship with Money with Elizabeth Husserl357. Is Your Work Worth It? How to Think About Meaningful Work with Jennifer Tosti-Kharas and Christopher Wong Michaelson275. Work, Parent, Thrive with Yael Schonbrun245. Family Firm with Emily Oster206. Fair Play Part 2 with Eve Rodsky176. Fair Play with Eve Rodsky174. How to Work and Parent Mindfully with Lori Mihalich-LevinSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Patrick Duddy, Visiting Senior Lecturer at Duke University & Former U.S. Ambassador to Venezuela for both President Bush and President Obama speaks on the US capture of Nicholas Maduro and potential outcomes for Venezuela. He speaks with Bloomberg's Romaine Bostick and Katie Griefeld. See omnystudio.com/listener for privacy information.

Send us a textWhat if cancer didn't have to be eradicated, but could be remembered, monitored, and controlled by the immune system itself?In this episode of Causes or Cures, Dr. Eeks speaks with Dr. Zachary Hartman, the lead researcher who revisited an extraordinary breast cancer vaccine trial conducted over 20 years ago. The trial involved a small group of women with advanced breast cancer. Women who, remarkably, are all still alive today.By analyzing their blood decades later, the research team discovered that these women still carried immune cells capable of recognizing their cancer, suggesting durable immune memory lasting more than two decades. (Study link here.)We discuss:The original breast cancer vaccine trial and what it was designed to do, in plain languageWhat it was like to discover that the women from the trial was still alive more than 20 years laterHow the immune systems of these women continued to recognize cancer cells long after the trialWhat CD27-positive immune cells are and why they matter, explained simplyWhy helper CD4 T cells may be just as important, or more important, than killer CD8 T cells when it comes to cancerWhat happened when researchers combined a CD27-boosting antibody with a cancer vaccine in miceWhat surprised the research team mostThe challenges of translating findings from mice to human trialsWhether cancer could someday be managed long-term by the immune systemHow generalizable this immune memory might be across different cancersWhat this research could mean for how we think about vaccines in a post-pandemic worldThe one key message the researcher hopes the public takes awayWhat's next in this line of researchThis episode offers a rare, hopeful (but scientifically grounded) look at how the immune system may be capable of remembering cancer for decades. Guest Bio: Dr. Zachary C. Hartman is an Associate Professor at Duke University in the Departments of Surgery, Pathology, and Integrative Immunobiology, where he also serves as Director of the Center for Applied Therapeutics and is a member of the Cellular and Molecular Biology and Genetics and Genomics programs. He earned his undergraduate degree from Northwestern University and completed his PhD at Duke University, followed by postdoctoral training in tumor immunology and breast oncology at Duke and the MD Anderson Cancer Center. In 2012, Dr. Hartman returned to Duke to establish a research program focused on tumor immunology and the development of cancer immunotherapies, including therapeutic vaccines, immune agonists, checkpoint inhibitors, antibody-based therapies, and strategies to stimulate anti-tumor immune responses.  Work with me? Perhaps we are a good match. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow Public Health is WeirdOr Facebook here.Or X.OnSupport the show

Lauren Schott was born in Akron, Ohio, and is a graduate of Duke University. She has spent twenty-five years working in publishing. Very Slowly All at Once is her first novel for adults. Spies, Lies and Private Eyes is copyrighted by Authors on the Air Global Radio Network #authorsofinstagram #authorinterview #writingcommunity #authorsontheair#suspensebooks#authorssupportingauthors #thrillerbooks #suspense #wip#writers#writersinspiration #books#bookrecommendations #bookaddict #bookaddicted#bookaddiction #bibliophile #read#amreading #lovetoread #terrencemccauley#terrencemccauleybooks #bookouture #thrillers#theuniversityseries #LaurenSchott #VerySlowlyAllAtOnce

Entrepreneur, nurse practitioner and Manhattan medspa founder Andi Assebian, MSN, AGNP-C, joins the podcast to share her journey from the Ivory Coast to the heart of New York City's aesthetic medicine scene. Drawing from her extensive background in physiology and perioperative nursing, Andi discusses how she built a practice that supports anatomy-driven beauty standards. She shares the stark reality of navigating the medical field as a woman of color and the determination required to scale a business while raising a family. You'll hear Andi discuss:   The Global Mirror: How growing up in the Ivory Coast and living across France and Canada shaped her view of beauty as a tool for identity and community rather than a quest for perfection. Precision Under Pressure: Andi shares insights from her time as an operating room nurse, exploring how that high-stakes environment still dictates her meticulous approach to patient safety and treatment plans today. Anatomy-Driven Aesthetics: Why she travels the globe to learn techniques that focus on balance and harmony over simple volume, and why the best aesthetic work should remain undetectable. The Courage to Ask: How asking for support and networking allowed her to expand from a single room to a thriving Midtown Manhattan practice in just two years. Rapid Fire Favorites: From the French classic Coq au Vin to the skincare trend she wants everyone to stop immediately. Important Links:Savvy Ladies (https://www.savvyladies.org/)Precious Williams' LinkedIn (https://www.linkedin.com/in/precious-l-williams/)Lisa Zeiderman's LinkedIn (https://www.linkedin.com/in/lisazeiderman/Important Links for Andi:Andi Assebian, MSN, AGNP-C's Site: https://dermartisan.com/About Andi Assebian, MSN, AGNP-C's:Andi is a board-certified Nurse Practitioner with extensive experience in medical aesthetics. She received her Bachelors in Physiology from University of Calgary, Nursing degree from Duke University, and Masters as a Nurse Practitioner from New York University.  She began her career in the operating room at Yale University hospital as a Perioperative Nurse and transitioned to NYC to work with world-class plastic surgeons and aesthetic practitioners. Andi founded Derm Artisan to share her passion and vision for a MedSpa – one built on an unwavering commitment to care, excellence and empowerment.  Andi has lived in France, Canada, U.S., the Ivory Coast. Her appreciation for different cultures, beauty standards, and people of all backgrounds is deeply reflected in the makeup of Derm Artisan. She is an avid learner and travels the globe to stay on top of the latest techniques and technologies. Andi currently lives in NYC with her husband and baby boy.  She enjoys spending time with family and friends, traveling, and is fluent in French a language that connects her to her roots and enriches the welcoming, multicultural spirit she brings into her practice each day. 

Dr. Bill Rafferty has dutifully committed much of his career to the critical issues of regulatory activities that govern Optometry, both in his home state of North Carolina but also nationally through ARBO.  He is a 1977 graduate of the UAB School of Optometry, and has had many professional roles in addition to clinical practice, including serving as faculty at Duke University and Wake Forest.  His stories include those who influenced him into health care, his family's citrus groves in Florida, and his service to our country through the National Guard.  He spent his early years in the VA and supported scope expansion efforts for Optometry.  Today he is Executive Director of the North Carolina State Board of Optometry where he cares passionately to support the profession and the public.   The Stories within the Story include: 1:03 The “What I Thought Optometry Would Be” Story 3:18 The Early Years Story 8:21 The Service to Country Story 10:04 The Optometry Training in the 1970's Story 13:01 The Mentors Story 16:57 The Early VA Efforts Story 18:50 The Duke University Story 21:12 The Educator Story 22:55 The Regulatory Affairs Story 30:53 The Optometry-Ophthalmology Story 39:20 The Joy Story 40:58 The Words of Inspiration Story   Runtime:  46 min.

About Luis Garcia:Luis Garcia is a seasoned international executive with over 25 years of experience in technology, digital media, and education, specializing in driving new ventures and products to rapid growth by building effective teams that harness innovation, technology, and creativity. He is the president of PETE, an Orlando-based tech startup that enables organizations to deliver personalized workforce learning at scale using AI. Before joining PETE, Luis spent nearly twenty years at Full Sail University, where, as VP of Full Sail Online and VP of Emerging Technologies, he helped establish the institution as a pioneer in online education. Earlier in his career, he served as Vice President of Product Development at quepasa.com and holds an MBA from the Fuqua School of Business at Duke University. In this episode, Dean Newlund and Luis Garcia discuss:Scalable training challenges in small and mid-sized organizationsInstructional design versus training delivery rolesAI-powered learning and simulation technologyTeaching soft skills through self-paced educationBalancing technology and human interaction at work Key Takeaways:Replace shadowing-based onboarding with self-paced courses that can stand alone without relying on expert trainers.Separate instructional design from subject matter expertise to create training that scales without pulling leaders away from their jobs.Use AI-driven simulations to allow employees to practice real conversations like de-escalation and customer objections before facing them in real life.Design training around clear learning outcomes so employees can demonstrate applied behavior, not just memorized information. "AI is an enabler to supercharge the human, and not to replace it.” — Luis Garcia Connect with Luis Garcia:  Website: https://www.pete.com/LinkedIn: https://www.linkedin.com/in/luisegarcia/   See Dean's TedTalk “Why Business Needs Intuition” here: https://www.youtube.com/watch?v=EEq9IYvgV7I Connect with Dean:YouTube: https://www.youtube.com/channel/UCgqRK8GC8jBIFYPmECUCMkwWebsite: https://www.mfileadership.com/The Mission Statement E-Newsletter: https://www.mfileadership.com/blog/LinkedIn: https://www.linkedin.com/in/deannewlund/X (Twitter): https://twitter.com/deannewlundFacebook: https://www.facebook.com/MissionFacilitators/Email: dean.newlund@mfileadership.comPhone: 1-800-926-7370 Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it.

In this episode, Anthony Cheung is joined by Harvey Bracken-Smith, founder of the Personable podcast and incoming Goldman Sachs summer intern, to unpack his remarkable journey from a small island in Jersey to Eton, Duke University, and beyond. Harvey shares insights on overcoming imposter syndrome, the power of consistency, building a personal brand, and how he's managed to interview billionaires, CEOs, and Olympic athletes before the age of 21. He also opens up about the importance of family, dealing with personal loss, and why his mantra is simply: Why not you?Whether you're navigating university, career uncertainty, or starting your own venture, this is a masterclass in mindset, grit, and taking action.(00:00) From Jersey to Wall Street(02:00) Eton Reality Check & Choosing the US Over the UK(07:51) Lifestyle & Opportunity: UK vs US vs Australia(15:59) Launching the Podcast: Purpose Over Prestige(21:30) Consistency Greater Than Talent(24:34) How to Land Guests: Confidence & Cold Approaches(31:11) The Secret Characteristic of Success(36:37) Handling Rejection: From 1,000 Emails to One "Yes"(45:45) What Actually Gets You Hired in Finance(50:30) Final Message: Why Not You?

On this week’s In Black America, producer and host John L. Hanson, Jr. presents a tribute to the late John Hope Franklin, a noted scholar of African American history, whose career of more than 60 years in scholarship, teaching and advocacy included a distinguished professorship at Duke University, helping prepare the landmark Supreme Court case […] The post John Hope Franklin, Jr. (Ep. 05, 2026 re-broadcast) appeared first on KUT & KUTX Studios -- Podcasts.

America is suffering from a loneliness epidemic. Some groups have suggested religious communities may be key to solving it. Could it help? Those arguing “yes” say it gives people regular social contact, support systems, and a sense of purpose that could combat isolation. Those arguing “no” say that secular options would provide better, broad-based solutions. Now we debate: Can Religion Cure the Loneliness Epidemic?    Arguing Yes:   Harold Koenig, Director of Duke University's Center for Spirituality, Theology and Health   Chris Murphy, Senator from Connecticut     Arguing No:  Ruth Whippman, Author of "America the Anxious: How Our Pursuit of Happiness Is Creating a Nation of Nervous Wrecks" and "BOYMOM: Reimagining Boyhood in the Age of Impossible Masculinity."  Dan Barker, Co-President of the Freedom from Religion Foundation  Emmy award-winning journalist John Donvan moderates  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Making the case for a better at home A1C test. Orange Biomed is developing a compact, one-drop, at-home A1C testing device they say could make frequent A1C checks easier and more accessible than ever. They're passionate about closing the gap for people who struggle to get to clinics regularly… and the research they share is compelling: four A1C tests a year can lead to a nearly 4% reduction in A1C levels. We'll talk about why more frequent A1C monitoring matters—even in the era of continuous glucose monitoring—how their new device works, and what early clinical trial results look like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Orange BioMed here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com    Episode transcript:   Stacey Simms  00:05 Today on diabetes connections, making the case for a better at home A1C test. Orange biomed is developing a compact, one drop device that they say could make frequent A1C checks easier and more accessible. They're sharing research that four A1C tests a year can lead to a nearly 4% reduction in A1C levels, but they say a lot of people can't get to the clinic that much. We'll talk about why this matters, even in the era of CGM, how the device works and what the early clinical trial results look like.   This podcast is not intended as medical advice. If you have those kinds of questions, please contact your healthcare provider.   Welcome to a bonus episode of diabetes connections. I hope your December is going well and that you know somehow you're able to take some time for yourself in the middle of all the holiday rushing around this time of year can be magical and stressful and exhausting and wonderful, and you know, all the things. And it's the same thing over here, super busy getting all this stuff done before the end of the year. Love it. But, you know, getting podcast episodes out, writing all the things we write and planning for next year, as they say, We're staying booked and busy.   But quick behind the scenes here to better explain this episode, I taped this interview way back over the summer during the ADA Scientific Sessions conference. I had some technical problems. I actually thought I lost this interview. There were two interviews that seemed to have gone missing. We're going to air the other one very soon. But thankfully, I do have backups upon backups. So all the info that you're going to hear today is still relevant.   This product, a small A1C test, is still in development. The only dated bit is about their follow up event that took place in August. Orange Biomed was launched in 2021 in South Korea, with its US headquarters in Providence, Rhode Island. Its founders are two Duke University alums, and they're my guests, CEO Yeaseul Park and Co-President Unghyeon Ko, We are also joined by Janice Dru-Bennett. She is a senior advisor at the company. Now, English is not the first language of two of these three speakers. This is a good time to remind you that most podcasting platforms have pretty good transcription services these days, especially Apple, I think they have a fantastic real time transcription service for podcasts that has been impressive to me in how they translate diabetes language. They're getting better at it. But I am also going to put a transcript of the interview in the show notes, which I don't normally do because the podcast services have gotten so good at it, but I think it could be helpful for at least a few of you out there. Okay, here is my conversation from the floor of ADA from the team at Orange biomed.   Yeaseul Park, Janice Drew Bennett and Dr Ko, Welcome to diabetes connections. I can't say live from ADA, because we're taping this to air later, but you're all there. Thank you so much for joining   Yeaseul Park  03:08 me. Yes, thank you. We're   03:10 excited to be here. Oh   Stacey Simms  03:11 my goodness. Can I ask first, how is the trip? I mean, yes, let me ask you. You guys came a long way.   Yeaseul Park  03:17 Yeah, it was 13 hours from Korea. But it's I'm so excited, because this event is really one of the times, and this is actually our third time attending ADA.   Stacey Simms  03:31 That's great. And we have so many questions for you, but Janice, let me ask you, you're there as everybody's setting up at the kind of beginnings of the show. What is it like right now for people who aren't familiar with ADA,   Janice Dru-Bennett  03:42 yes, you can hear the hammers in the background, although, but not on this podcast, but there's a lot of noise and people walking by. We're just setting up this the day before the exhibit hall opens and Dr Cole will be presenting at the Innovation Hub tomorrow, which is where we're sitting right now, with tables of innovators will be showcasing their diabetes innovations, and   Stacey Simms  04:04 there's a lot to get to. Dr Koh, I know you're presenting, but yes, let me ask you, like, what why? I know you said it's your third year, but why is orange biomed at ADA, what is your goal   Yeaseul Park  04:16 for us? ADA, is for a learning experience. As well as a platform to share. We come to see how all those around the world are fighting against diabetes, whether through clinical research, digital tools or technologies or community programs. At the same time, you're so proud to hear what orange biomat is building anytime, and eight months exhausting. That makes diabetes monitoring not accessible, not so many. And this year is especially exciting because Dr ko our co founder of orange buying at the group of speaking at ADA brand new program the innovation Hall.   Stacey Simms  04:58 That's awesome. So Dr Koh, tell me. Little bit about this, the Innovation Hub is pretty cool, but what are you going to be talking about?   Unghyeon Ko  05:05 Yeah, actually, I'm talking about the engineering part. I mean our technology, so our orange biomed, we are trying to solve a simple but a serious problem about the A1C accessibility. So to increase the A1C accessibility. So we are, we are developing at home device to measure the A1C level. So I'm, I'm talking about how difficult to increase the accessibility of A1C, but our technology is handled that difficult problem. So we now he's so agreed. So I'm going to introduce our technology and emphasize the importance of the A1C measurement at home.   Stacey Simms  05:49 Yeah, so A1C, it's interesting. My son was diagnosed at two, and in the pediatric world, you know, they'll just prick a finger generally and have that A1C right away. But my husband lives with type two, and he gets his labs drawn. And then it takes forever. So tell me a little bit before we go further about what you're hoping to do and making this easier for the patient,   Speaker 1  06:10 the frequent monitoring of A1C is so important to prevent the diabetic complications. So the money, so if you there is some so I can say that there is a research that if you measure the A 1d the four times a year, the People's A1C level is decreased like 3.8% but if you measure the A 1d at one per year, Then the A1C level is increased 1.5% so the frequent A1C monitoring is so important to prevent the diabetes complications. But problem is A1C measurement is only available at clinical site at this moment, so most of the A1C monitoring is done by the clinical side. So that's why people are difficult to monitoring A1C, because they have to visit the clinics forever. So is so like four times, or even eight times visit the clinics or hospital is quite difficult, especially in the people living in the far area from the hospital. So that's why the home A1C test is required. So I think that's why the accessibility of the A1C is one of the important things in managing the diabetes complications.   Stacey Simms  07:39 Dr Koh, is there evidence that, I mean more frequent A1C testing, I think would give many people peace of mind, perhaps. But is there evidence that it really does help in your health?   Speaker 1  07:51 Oh, yes, it is actually like from there is the research, like the famous research about the A1C level, like the research name this t and this research proved that the A1C is the one of the strongest predictor of diabetes complication. So A1C is completely related with the risk of diabetes complication. So like keeping A1C on the 7% dramatically lower the risk of diabetes complications. And also, there is another research in UK, the UK PDS study, and that study said they are A1C. Lowering A1C by just 1% can reduce overall mortality by 15% and microvascular complication by 37% so the roaring A1C is the goal of the treatment of the   Yeaseul Park  08:47 diabetes. So   Stacey Simms  08:48 when I think of at home diabetes tests, blood tests, seem like they're they're really sensitive, right? You have to be very careful with things like that, although we do, we did finger sticks at home for years and years. Are there challenges with at home A1C testing that that people like me could mess up,   Yeaseul Park  09:06 sure actually when I was doing pandemic outside system? So it's a new   Yeaseul Park  09:19 box of mustard with five or six needles inside, and we need to collect this blood to sound the left result. But then I really tried to collect the requirement matter blood, which is like it was like bleeding. Oh, it's not just retiring in one block, one drop of block, but it's like you need to try, yeah, many times, not just in one spot, to collapse in the block. And the other way you. Built female in, built a lot more broadly, to store your venous blood, and that's features like discomfort.   Stacey Simms  10:10 Would you mind taking us through your experience with the A1C testing? You were talking about how much blood it took? Yeah.   Yeaseul Park  10:17 So it, it requires many, many drops of blood. So I felt like it's like bleeding, and you make a lot of mess around the table. And so I felt, even though it's it was a topic time it was pandemic. So that's the only option I had at that time, but I wanted to make it simple and easier. And the other types of point of care devices only use a drop of blood still have some limitations, because we all don't want to bleed too much, so sometimes we try to finger stick very small and just squeeze to get enough blood. But if you squeeze to get enough sample volume, that's make your other liquid, like sweats, can also mix with your blood, and that actually affects the accuracy of the testing usually so many point of care devices also not recommend you to squeeze to get enough blood, so that means you need to treat a little too deep to get enough. So we really wanted to make this whole process or simpler and more problem.   Stacey Simms  11:43 Can you share a little bit about what the device looks like, what the patient experience is when they use it?   Speaker 1  11:48 Dr, CO, so our device is a palm size. Is in most like, like self, self poem, so it's a palm size device. So our device has no switch, but there is only a slider in the front of the device. So if you slide that, you can the device is turned on and you can insert the cartridge, and the cartridge is disposable cartridge. So after that, you just collect your blood and dilute it in the collecting tube and drop the sample into the cartridge, then analyze the A1C like automatically. So it's quite similar with the covid by covid test kit. So the covid test kit collect the sample in your nose and mix with the Rickett and drop it right? And it's quite similar.   Stacey Simms  12:45 So do you do a finger stick to put on the cartridge? How much blood to yells? Point, you know? How much blood do you need?   Speaker 1  12:52 Our devices for home use device, so it's quite we use a very different technology, because our device analyze the red blood cell one by one. So actually, we don't need exact unlike like five micro or 10 micro, we don't need the exact sample block. So we just need one drop of blood. So if the one drop is big, or if the one drop is right or small, it's fine for us. So one drop of blood, mix with their sample and drop one drop onto the cartridge. So maybe you can, you can drop one more than one drop, but we recommend one drop. So one drop of blood sample my dinner the rest yesterday pointed out that the skeezing the finger of blood is a problem for other device because, because in our body, there is a body wicked inside your under, under your skin. So if the body wicked is mixed with the blood samples, so it might be a problem because it dilute the blood sample. But our device, we analyze the Red Cross itself. So if it is diabetes, I think so we will find so you just puncture very best, and if you scale it, and it's totally fine for us. So it's, it's one of the good point of our device.   Yeaseul Park  14:20 How long does it take to get the results? It takes like, five minutes. Okay, yeah, and that's all at home. Yeah. Yezel, who do you see using this? Who is this for? Basically, it's for everyone. I think whoever has pre diabetes, diabetes type one, type two, and especially, I think who has limited access to primary care or lab testings. You know, many people who are older, tends to have more, especially the people who has limited access to primary care or lab testings. We believe this device can give more value to them. Yeah, and especially some people who have limited mobility, if they are older, or if they have experienced that amputation or something like that, they cannot go to the hospital by themselves. They need a caregivers to drive them to the hospital for the simple lab testing. But now I think it empowers patients who has that limitation still can take control their health by using this kind of home use device. How accurate   Stacey Simms  15:33 is it? I assume you have studies, and you've done some trials on how on the accuracy?   Yeaseul Park  15:37 Dr, CO, do you want to add that?   Speaker 1  15:40 Oh, yeah. So we are preparing the clinical trial. So the official clinical trials will be done within this year, but so that's our plan. But we we tested our device already using the in in last year. So last year, feasibility studies show that our device is quite similar with other point of care devices, and hopefully because at that time, our device, our especially our cartridge sensor, we just manufacturing our own like our in our lab. So this time, the official clinical trial in in this year, we are going to manufacturing in the factories so it might be more precise. So we hopefully we trying to chase the hospital accurate.   Stacey Simms  16:30 And I have to ask, where more and more people with diabetes are wearing a CGM and looking at time and range. What would you say to people who would tell you, well, we don't really need A1C anymore. We have time and range. Dr Cody, I see you nodding. Go ahead, yeah, yeah.   Speaker 1  16:47 So that's a very important point, but because the timing range is also important, and the CGM is very great technology for diabetes people. But problem is, like the A1C and C GM target different, like the CGM target the hypothesemia, but the A1C targeting the diabetes complications. So like, if you measure the timing range and you can manage your average glucose more nicely, but it might be prevent your hypothenia. But if you want to assess your diabetes management, you might be measure A1C. So if you measure timing range, but you also have to measure the A1C. So A1C is for everyone's and so. And also, the point is, if you don't treat the insulin, or if you don't treat the any medications, then you don't need to actually using the CGM, that's the ADH recommendation. So, but in in that case, you need the A1C as well. So A1C for everyone, and the CGM is for the people who treated the insulin. That's the ADA guide, right? And then,   Stacey Simms  18:12 yes, let me just ask you. You know, you came all this way. As you say, this is your third time at ADA. Trials are starting soon. What's your hope here? Is this something you see in homes of everyone who has any kind of diabetes? What's the big goal for Orange biomed?   Yeaseul Park  18:28 Every time we talk to a day, we can feel what's going on here in diabetes industry. It's a huge maybe first year, I the most frequently hard keyword was aid system. But after that, we now have GLP one, and now we hear more keyword around obesity. So that's a little slightly different trend I can feel. And once you come and join this full sessions, then I can see there's make everyone is making a progress, and we are all together. Want to fight against diabetes in their own way or with their own expertise, whether it's pharmaceutical, whether it's medical device or diabetes, sex, sometimes any other community programs that really support this patient and families, the community, and it's Really this whole atmosphere actually really motivates our team and myself, and we can feel the value. I can really feel this we are doing something valuable to patients and our community, and that's the most great thing, like the greatest thing that I can take when I come back to home with a. After the ADA. And for sure, we want to have opportunity to make voice what we are doing at Orange biomed, and want to deliver this value to the patient and other healthcare professionals. Otherwise, even though we are working hard to make this progress, no one knows, and that makes any changes the world. So that's the important purpose we are coming here. That's great.   Stacey Simms  20:30 Janice, before I let you all go, I know you wanted to talk about an event you've got coming up in Chicago. Can you tell me a little   Janice Dru-Bennett  20:37 bit about that? Yes, we're really excited for Orange biomed to be hosting the first map your health event, a local event here in Chicago, we have done a solving healthcare challenges webinar to announce our map your health campaign, which is, monitor your A1C, monitor your health and then adapt your treatment and prevent chronic disease. And we're actually going to be hosting on August 16, from 10am to 3pm in Chicago at their humble Park, Health Wellness Center, the first local event, inviting all local partners. We'll have some virtual sessions, showcase with yoga or ask the endocrinologist. So we'll have a very exciting agenda that both virtual and on site participants can join in, eat healthy foods. See, see what's in Chicago from a screenings perspective, and really get people motivated to map your health. So hashtag, map your health. Tell your your your health story, and let's get everyone, um, healthier. Wow.   Stacey Simms  21:35 Okay, fantastic. Well, yes, I'll park Dr co Janice, thank you so much for joining me. Have a terrific show. I know this is an audio podcast, but especially behind you. Yassil, it has been wild to watch the construction guys are going by and motorized carts and things are going up behind you. So have a wonderful ADA. Keep us posted, and we'll get the word out about your event in August and going forward. Thanks so much for joining me.   more information in the show notes about the studies and about orange biomed. You can sign up for alerts and emails from them as their product moves forward. So if you're interested, definitely check that out. Thank you to my editor, John Bukenis from audio editing solutions, thank you so much for listening. I'm Stacey Simms. I'll see you back here soon. Until then, be kind to yourself.   Benny  22:30 Diabetes Connections is a production of Stacey Simms media. All Rights Reserved, all wrongs avenged.    

In this episode, Kuldip R. Patel, PharmD, FASHP, Senior Associate Chief Pharmacy Officer at Duke University Health System, discusses how pharmacy services are expanding across the continuum to reach more patients and improve outcomes. He shares insights on supply chain resilience, ambulatory and inpatient pharmacy growth, and the technologies shaping the future of pharmacy practice.

As we age, we come to appreciate the holiday traditions of our youth. Ricky Mullins (University of Virginia at Wise) remembers receiving treat bags at his small, backroads church. The poke bags were stuffed oranges, peanuts, cracker jacks and sometimes even a chocolate bar. Now, he's passing the tradition along to the youth at the church that he pastors. And: Mary Lou Williams was a renowned jazz pianist and composer. She brought sacred Black jazz music to Duke University's chapel every year. Gayle Murchison (William and Mary) shares some of Williams' music with us. Later in the show: How Ryan Stouffer (Longwood University) learned the value of fellowshipping over food from his dad's rib spot. Plus: Mary Beth Matthews (Mary Washington) walks us through how the American traditions of Hanukkah and Christmas have changed over the years.

Court Lorenzini is the founder and CEO of multiple successful technology startups including DocuSign, Point.com, Primus BioVision and MetaBrite Inc. His latest venture, FounderNexus, aims to triple the success rate of venture-backed startups, and his work with the Lorenzini Family Foundation is aggressively investing in building a stronger and more equitable society. Additionally, Mr. Lorenzini serves on the Boards of many early-stage companies across the US and UK as well as the United States Olympic and Paralympic Foundation, and is an active investor and advisor. Over his career, Mr. Lorenzini has raised over $300M in venture and strategic funding from leading corporations and venture capital funds. Prior to his entrepreneurial ventures, Mr. Lorenzini held senior management positions with Cisco Systems and KLA-Tencor, including two years running a technology business in Neuchatel, Switzerland. He holds a Bachelor of Science in Mechanical Engineering from Duke University and post graduate credentials from Stanford University, UC Berkeley and University of Wisconsin at Madison.See omnystudio.com/listener for privacy information.

Betsy Pepine is a Best-Selling author, Founder, CEO, and serial entrepreneur in real estate who is passionate about helping at-risk families with children. She founded a 501( c ) 3 non-profit foundation called Pepine Gives, which helps families who are facing housing insecurity. Betsy also earned an economics degree from Duke University and an MBA from The Wharton School of Business at the University of Pennsylvania, and her work has been endorsed by Shark Tank's Barbara Corcoran as well as media personalities Dave Ramsey and Glenn Beck. Her best-selling book is titled "Breaking Boxes: Dismantling the Metaphorical Boxes that Bind Us," where she encourages readers to transform their mindset and challenge norms to live the life they want and deserve. Betsy shares her fascinating journey as well as valuable tips and insights on how all of us can live our lives to the fullest by breaking boxes, transforming our mindset, and challenging norms. Download this uplifting, positive, and empowering episode to hear her story and discover how to live life on your terms! Connect with Betsy:     https://www.betsypepine.com/ https://www.facebook.com/betsypepine https://www.youtube.com/@BetsyPepine https://www.instagram.com/betsypepine/ https://www.linkedin.com/in/betsypepine/ https://www.tiktok.com/@gainesvillerealtor https://substack.com/@betsypepine Want to be a guest on TheFemiNinjaProject? Send Cheryl Ilov a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/1620842117560x116520069523704300  

Today, Dave Furfaro, Luke Hedrick, and Robert Wharton discuss the PREDMETH trial published in The New England Journal of Medicine in 2025. This was a non-inferiority trial comparing prednisone to methotrexate for upfront therapy in treatment-naive sarcoidosis patients. Listen in for a break down of the trial, analysis, and clinically applicable pearls. Article and Reference Todays’ episode discusses the PREDMETH trial published in NEJM in 2025. Kahlmann V, Janssen Bonás M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk HNAJ, van der Maten J, Marges ER, Moonen LAA, Overbeek MJ, Koopman B, Loth DW, Nossent EJ, Wagenaar M, Kramer H, Wielders PLML, Bonta PI, Walen S, Bogaarts BAHA, Kerstens R, Overgaauw M, Veltkamp M, Wijsenbeek MS; PREDMETH Collaborators. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. N Engl J Med. 2025 Jul 17;393(3):231-242. doi: 10.1056/NEJMoa2501443. Epub 2025 May 18. PMID: 40387020. https://www.nejm.org/doi/full/10.1056/NEJMoa2501443 Meet Our Hosts Luke Hedrick is an Associate Editor at Pulm PEEPs and runs the Rapid Fire Journal Club Series. He is a senior PCCM fellow at Emory, and will be starting as a pulmonary attending at Duke University next year. Robert Wharton is a recurring guest on Pulm PEEPs as a part of our Rapid Fire Journal Club Series. He completed his internal medicine residency at Mt. Sinai in New York City, and is currently a first year pulmonary and critical care fellow at Johns Hopkins. Key Learning Points Clinical context Prednisone remains the traditional first-line treatment for pulmonary sarcoidosis when treatment is indicated, with evidence for short-term improvements in symptoms, radiographic findings, and pulmonary function—but with substantial, familiar steroid toxicities (weight gain, insomnia, HTN/DM, infection risk, etc.). Despite widespread use, glucocorticoids haven't been robustly tested head-to-head against many alternatives as initial therapy, and evidence for preventing long-term decline (especially in severe disease) is limited. Immunosuppressants (like methotrexate) are often used as steroid-sparing agents, but guideline recommendations are generally conditional/low-quality evidence, and practice varies. Why PREDMETH matters It addresses a real-world question: Can methotrexate be an initial alternative to prednisone in pulmonary sarcoidosis, rather than being reserved only for steroid-sparing later? It also probes a common clinical belief: MTX has slower onset than prednisone (often assumed, not well-proven). Trial design (what to know) Open-label, randomized, noninferiority trial across 17 hospitals in the Netherlands. Included patients with pulmonary sarcoidosis who had a clear pulmonary indication to start systemic therapy (moderate/severe symptoms plus objective risk features like reduced FVC/DLCO or documented decline, plus parenchymal abnormalities). Excluded: non–treatment-naïve patients and those whose primary indication was extrapulmonary disease. Treat-to-tolerability with escalation: both drugs started low and were slowly increased; switch/add-on allowed for inadequate efficacy or unacceptable side effects. Primary endpoint: change in FVC (with the usual caveat that FVC is “objective-ish,” but effort-dependent and not always patient-centered). Noninferiority margin: 5% FVC, justified as within biologic/measurement variation and “not clinically relevant.” Outcomes assessed at weeks 4, 16, 24; powered for ~110 patients to detect the NI margin. Patient population (who this applies to) Mostly middle-aged (~40s) with mild-to-moderate physiologic impairment on average (FVC ~77% predicted; DLCO ~70% predicted). Netherlands-based cohort with limited Black representation (~7%), which matters for generalizability. Would have been helpful to know more about comorbidities (e.g., diabetes), which can strongly influence prednisone risk. Main findings (what happened) Methotrexate was noninferior to prednisone at week 24 for FVC: Between-group difference in least-squares mean change at week 24: −1.17 percentage points (favoring prednisone) with CI −4.27 to +1.93, staying within the 5% NI margin. Timing mattered: Prednisone showed earlier benefit (notably by week 4) in FVC and across quality-of-life measures. By week 24, those early differences largely washed out—possibly because MTX “catches up,” and/or because crossover increased over time. In their reporting, MTX didn't meet noninferiority for FVC until week 24, supporting the practical message that prednisone works faster. Crossover and analysis nuance (important for interpretation) Crossover was fairly high, which complicates noninferiority interpretation: MTX arm: some switched to prednisone for adverse events and others had prednisone added for disease progression/persistent symptoms. Prednisone arm: some had MTX added. In noninferiority trials, heavy crossover can bias intention-to-treat analyses toward finding “no difference” (making noninferiority easier to claim). Per-protocol analyses avoid some of that but introduce other biases. They reported both. Safety signals (what to remember clinically) Adverse events were very common in both arms (almost everyone), mostly mild. Side-effect patterns fit expectations: Prednisone: more insomnia (and classic steroid issues). MTX: more headache/cough/rash, and notably liver enzyme elevations (about 1 in 4), with a small number discontinuing. Serious adverse events were rare; numbers were too small to confidently separate “signal vs noise,” but overall known risk profiles apply. Limitations (why you shouldn't over-read it) Open-label design, and FVC—while objective-ish—is still effort-dependent and can be influenced by expectation/behavior. Small trial, limiting subgroup conclusions (e.g., severity strata, different phenotypes). Generalizability issues (Netherlands demographics; US populations have higher rates of obesity/metabolic syndrome, which may tilt the steroid risk-benefit equation). Crossover reduces precision and interpretability of between-group differences over time. Practice implications (the “so what”) For many patients with pulmonary sarcoidosis needing systemic therapy, MTX is a reasonable initial alternative to prednisone when thinking long-term tolerability and steroid avoidance. Prednisone likely provides faster symptom/QoL relief in the first weeks—so it may be preferable when rapid improvement is important. The trial strengthens the case for a patient-centered discussion: short-term relief vs side-effect tradeoffs, and the possibility of early combination therapy in more severe cases (suggested, not proven).

Dr Mark Palmeri is a professor at Duke University in the Biomedical Engineering (BME) field. He joins Chris to talk about using open tools (KiCad, ngspice, Zephyr, Jupyter notebooks, Python) to build educational resources and how he shares those courses with the world outside of Duke. He also walks through the Tympanometer project, built with Duke BME Design Fellows.

In this episode of the NCS Podcast Perspectives series, host Nicholas Morris, MD, speaks with Cherylee Chang, MD, division chief of neurocritical care and professor of neurology, neurosurgery and medicine at Duke University. Dr. Chang reflects on her journey from an early interest in cardiothoracic surgery to neurology, and ultimately, to the "intersectional" work that drew her to neurocritical care. She discusses her early training in the field, efforts to establish certification and fellowship accreditation pathways and the challenges of defining the essential components of what constitutes neurocritical care. Dr. Chang also shares insights from Duke's advanced practice provider model, her work to broaden multidisciplinary inclusion within NCS and her current focus on leadership development, workforce shortages and strategies to better attract the next generation to the field. Dr. Chang recommends the following books for those interested in developing their leadership potential:Difficult Conversations by Douglas Stone, Bruce Patton and Sheila HeenExtreme Ownership by Jocko Williams Leadership and Self-Deception by The Arbinger InstituteThe Fearless Organization by Amy EdmonsonThe Leader's Guide to Mastering Feedback by Joan HibdonThe Let Them Theory by Mel Robbins The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

Today, Dr. Holmes talks with neurodivergent psychiatrist, Dr. Stacy Greeter.Topics discussed:Dr. Greeter's diagnosis journey at the age of 40 as a practicing psychiatrist.Growing understanding of AutismMyths about AutismDifferent presentations of girls/women in AutismGender Fluidity & AutismMedications and How to be a psychiatric patient and advocate for yourself as an autistic patient About our Guest:Dr. Stacy Greeter is board-certified in both child/adolescent and adult psychiatry. She collaborates with children, adults, and their families to design a comprehensive individualized treatment plan. Dr. Greeter graduated summa cum laude from Duke University, where she was inducted into the Phi Beta Kappa Honor Society and received her Doctor of Medicine degree from the University of North Carolina at Chapel Hill under the Morehead Medical Scholarship. During her undergraduate and medical training, Dr. Greeter conducted extensive clinical research funded by the Howard Hughes Medical Institute on autism and on OCD. She completed both her adult studies and her child and adolescent subspecialty training at Northwestern University in Chicago, where she trained with nationally and internationally renowned psychiatrists. She is also certified in Internal Family Systems Therapy. More info: https://www.stacygreetermd.com/about-us Disclaimer:When we have guests on the ASR podcast, they are recognized for their expertise in autism as advocates, self-advocates, clinicians, parents, or other professionals in the field. They may or may not be part of the faith community; having a guest on the broader topic of autism does not reflect complete agreement with the guest, just as many guests may disagree with our faith perspective. Guests are chosen by topic for the selected podcast discussion and are not necessarily in complete agreement with all the beliefs of the selected guest(s).

Dorie Clark is an executive education professor at Duke University's Fuqua School of Business and Columbia Business School, and is the bestselling author of several books, including The Long Game and Stand Out. A frequent Harvard Business Review contributor, she has consulted for leading organizations including Google, Microsoft, and the World Bank. Dorie is former presidential campaign spokeswoman, an award-winning journalist, and a four-time Thinkers50 honoree who was named the world's top communication coach by the Marshall Goldsmith Leading Global Coaches Awards. Dorie holds degrees from Smith College and Harvard Divinity School. In this episode we discuss the following: While Dorie was working grueling hours on the campaign trail for low pay, her boss was earning 10 times her monthly salary in one hour speeches—and that sparked Dorie's curiosity. She realized that the massive pay difference came down to scale. Even if Broadway actors are just as talented as Hollywood actors, the Hollywood actors reach millions more people, thus commanding a premium. Dorie also saw that her boss had earned trust of other high status people who vouched for him. By building up social proof through brand affiliations, media appearances, and content creation, we make it easier for people to trust us. And we can also increase our scale. 

Today Razib talks to Sean Trende. He is a prominent American political analyst who currently serves as the Senior Elections Analyst for RealClearPolitics, a position he has held since 2010. He is also a Fellow at the American Enterprise Institute (AEI) and a lecturer at The Ohio State University, where he earned his Ph.D. in political science in 2023. Before transitioning to full-time political analysis, Trende practiced law for eight years at firms including Kirkland & Ellis LLP and Hunton & Williams LLP, holding a J.D. and M.A. from Duke University and a B.A. from Yale University. Known for his expertise in election forecasting, redistricting, and political demographics, he authored the book The Lost Majority (2012), co-authored The Almanac of American Politics 2014, and served as a court-appointed special master to redraw Virginia's legislative districts in 2021. Trende and Razib first talk about the elections in the fall of 2025 in Virginia and New Jersey, and what they tell us about the elections next year. They also discuss the election of Zohran Mamdani in New York City, and the rise of populism on the Left and Right. Razib asks Trende about why political commentary often assumes single-party rule is about to happen, only to be refuted by the reality of the opposition's resurgence once these claims are made. They also talk about Trende's distinctive personal background, and his perspective as a more centrist-libertarian commentator and professor in the political analyst field.

In this episode of Behind the Knife, the minimally invasive surgery (MIS) team dives deep into the evolving field of common bile duct exploration (CBDE). From the historical context of laparoscopic approaches to the latest advances including robotic-assisted techniques, Drs. Shaina Eckhouse, James Jung, Zachary Weitzner, and Joey Lew discuss key evidence shaping modern practice. Listeners will learn about indications and anatomy guiding trans-cystic versus trans-choledochal approaches, practical tips for safe stone clearance, and critical considerations around learning curves and team coordination for robotic procedures. The episode also highlights important studies comparing single-stage laparoscopic CBDE with staged ERCP and cholecystectomy, emphasizing outcomes such as stone clearance, pancreatitis rates, and hospital length of stay. This comprehensive overview is a must-listen for MIS and acute care surgeons interested in optimizing the management of choledocholithiasis and streamlining patient care with minimally invasive techniques. Hosts:  - Shaina Eckhouse, MD, Bariatric Surgery Medical Director and Vice Chair of Clinical Operations, Department of Surgery, Duke University - James Jung, MD, PhD, Assistant Professor of Surgery, Duke University - Zachary Weitzner, MD, Minimally Invasive and Bariatric Surgery Fellow, Duke University, @ZachWeitznerMD - Joey Lew, MD, MFA, Surgical resident PGY-3, Duke University, @lew__actually Learning Goals:  By the end of this episode, listeners will be able to: -  Describe the historical approaches to managing choledocholithiasis, including staged interventions and the evolution toward single-stage laparoscopic common bile duct exploration (CBDE). -  Summarize key clinical evidence comparing CBDE and ERCP, including landmark studies and meta-analyses evaluating outcomes, complications, and trends over time.​ - Distinguish between transcystic and transcholedochal approaches to CBDE, explaining indications, contraindications, and technical nuances for each technique.​ -  Identify appropriate candidates for transcystic exploration based on cystic duct anatomy and stone characteristics.​ - Recognize the impact of newer surgical technologies—such as digital choledochoscopy, Spyglass, and robotic platforms—on CBDE practice, efficiency, and safety.​ - Discuss the importance of multidisciplinary teamwork, preparation, and perioperative planning for successful CBDE, particularly in complex or altered anatomy cases.​​ - Appraise the learning curve and quality of evidence for new CBDE procedures, outlining the need for mentorship, ongoing training, and knowing when to collaborate with GI or hepatopancreaticobiliary (HPB) surgery.​ - Outline approaches and bailout strategies for challenging cases, including patients with surgically altered anatomy and use of adjuncts such as intraoperative cholangiography (IOC), feeding tube placement, and Fanelli stents.​​ - Evaluate safety outcomes and limitations associated with robotic-assisted CBDE and single-stage management, incorporating recent data from population-based studies.​ -  Reflect on strategies for tailoring CBDE techniques to individual patient anatomy, surgeon experience, and available resources, advocating for evidence-based practice and continuous learning. References: -  Giurgiu DI, Margulies DR, Carroll BJ, et al. Laparoscopic Common Bile Duct Exploration: Long-term Outcome. Arch Surg. 1999;134(8):839-844. doi:10.1001/archsurg.134.8.839 https://pubmed.ncbi.nlm.nih.gov/10443806/ -  Lyu Y, Cheng Y, Li T, Cheng B, Jin X. Laparoscopic common bile duct exploration plus cholecystectomy versus endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for cholecystocholedocholithiasis: a meta-analysis. Surg Endosc. 2019;33(10):3275-3286. doi:10.1007/s00464-018-06613-w https://pubmed.ncbi.nlm.nih.gov/30511313/ - Bekheit M, Smith R, Ramsay G, Soggiu F, Ghazanfar M, Ahmed I. Meta‐analysis of laparoscopic transcystic versus transcholedochal common bile duct exploration for choledocholithiasis. BJS Open. 2019;3(3):242-251. doi:10.1002/bjs5.50132 https://pubmed.ncbi.nlm.nih.gov/31183439/ - Cironi K, Martin MJ. Reclaim the duct! Laparoscopic common bile duct exploration for the acute care surgeon. Trauma Surg Acute Care Open. 2025;10(Suppl 1). doi:10.1136/tsaco-2025-001821 https://pubmed.ncbi.nlm.nih.gov/40255986/ - Zhang C, Cheung DC, Johnson E, et al. Robotic Common Bile Duct Exploration for Choledocholithiasis. JSLS J Soc Laparosc Robot Surg. 2025;29(1):e2024.00075. doi:10.4293/JSLS.2024.00075 https://pubmed.ncbi.nlm.nih.gov/40144383/ - Kalata S, Thumma JR, Norton EC, Dimick JB, Sheetz KH. Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy. JAMA Surg. 2023;158(12):1303-1310. doi:10.1001/jamasurg.2023.4389 https://pubmed.ncbi.nlm.nih.gov/37728932/ Ad Disclosure: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

A Trump executive order is giving retail investors more access to private markets. Is that a golden opportunity — or fool's gold? SOURCES:Elisabeth de Fontenay, professor of law at Duke University.Steven Kaplan, professor of entrepreneurship and finance at the University of Chicago. RESOURCES:"Democratizing Access to Alternative Assets for 401(k) Investors," (The White House, 2025)."The (Heterogeneous) Economic Effects of Private Equity Buyouts," by Steven J. Davis, John Haltiwanger, Kyle Handley, Ben Lipsius, Josh Lerner, and Javier Miranda (Management Science, 2025)."Risk-Adjusted Returns of Private Equity Funds: A New Approach," by Arthur G. Korteweg and Stefan Nagel (The Review of Financial Studies, 2025)."The Effects of Management Buyouts on Operating Performance and Value," by Steven Kaplan (Journal of Financial Economics, 1989). EXTRAS:"The Biden Policy That Trump Hasn't Touched," by Freakonomics Radio (2025)."Should Companies Be Owned by Their Workers?" by Freakonomics Radio (2024)."Do You Know Who Owns Your Vet?" by Freakonomics Radio (2023)."Are Private Equity Firms Plundering the U.S. Economy?" by Freakonomics Radio (2023). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.